Products

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC67402	Pomalidomide-15N,13C5 Featured	Pomalidomide-15N,13C5 is a stable isotope-labeled variant of pomalidomide (HY-10984), a third-generation immunomodulatory drug that functions as a cereblon-directed molecular glue. This compound mediates targeted ubiquitination and degradation of Ikaros family transcription factors (IKZF1/3) through recruitment of the CRL4CRBN E3 ligase complex, underpinning its therapeutic mechanism.
DC67403	KRAS ligand 4 Featured	KRAS ligand 4 (compound 2) is a SOS1-targeting bifunctional molecular glue that suppresses oncogenic signaling by degrading key KRAS pathway components, evidenced by reduced pERK and pS6 levels. It demonstrates broad-spectrum activity against diverse KRAS mutations, disrupting proliferation across resistant cancer models.
DC67404	QS-57 Featured	QS-57 is a bifunctional degrader that combines BRD4-targeting PROTAC activity with 14-3-3 molecular glue properties.
DC67405	Acetyl-cyclosporin A aldehyde Featured	Acetyl-cyclosporin A aldehyde is a chemically modified derivative of cyclosporin A (HY-B0579), featuring an acetyl group and a reactive aldehyde moiety. The parent compound, cyclosporin A, is a dual-function molecule that both inhibits calmodulin signaling and binds cyclophilin, thereby blocking NF-AT nuclear translocation and inducing mitochondrial dysfunction.
DC67406	EM12-FS Featured	EM12-FS is a bifunctional CRBN modulator that engages cereblon at His353 while functioning as a molecular glue to induce NTAQ1 degradation. Demonstrating favorable pharmacokinetics, it exhibits a human plasma half-life of 196 minutes, supporting its therapeutic potential.
DC67407	IKZF1-degrader-1 Featured	IKZF1-degrader-1 (Compound 9-B) is a highly potent molecular glue that achieves sub-nanomolar degradation of IKZF1 (DC50 = 0.134 nM), demonstrating significant therapeutic potential for targeting IKZF1-dependent malignancies.
DC67410	MRT-10350 Featured
DC67411	MRT-7612 Featured
DC67412	MRT-3486 Featured
DC67413	MRT-23227 Featured
DC67415	4’-α-C-Methyluridine Featured	4’-α-C-Methyluridine represents a structurally modified uridine analog with significant pharmacological potential. As a nucleoside derivative, it shares structural similarities with uridine—a compound recognized for its antiepileptic properties—while offering enhanced metabolic stability through its methyl modification.
DC60818	mono-Boc-Br MK-6240 Precursor Featured	mono-Boc-Br MK-6240 Precursor is the precusor of MK-6240.. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs .
DC67417	BAY 3389934 Featured	BAY 3389934 represents an innovative dual-action anticoagulant that simultaneously inhibits both Factor IIa (thrombin) and Factor Xa in the coagulation cascade. This unique mechanism provides comprehensive anticoagulation while demonstrating organ-protective properties in severe infections.
DC67418	Ulacamten Featured	Ulacamten is a novel, highly selective cardiac myosin inhibitor that directly targets the contractile machinery of heart muscle cells.
DC67419	PF-07853578 Featured	PF-07853578 (Example 11) is a highly potent and selective targeted protein degrader that effectively reduces PNPLA3 levels with an EC50 of 8 nM.
DC67420	AZD2389 Featured	AZD2389 represents a novel, orally bioavailable fibroblast activation protein (FAP) inhibitor with significant therapeutic potential.
DC67421	Enozertinib Featured	Enozertinib is a next-generation EGFR tyrosine kinase inhibitor demonstrating potent antineoplastic effects against EGFR-driven malignancies.
DC67422	Alixorexton( ALKS 2680) Featured	Alixorexton is a selective orexin-2 receptor (OX2R) agonist demonstrating significant metabolic modulation potential.
DC67423	BMS-986238 Featured	BMS-986238 represents an advanced macrocyclic peptide therapeutic that demonstrates potent and selective inhibition of PD-L1 immune checkpoint signaling.
DC67424	RP-1664 Featured	RP-1664 is a novel, orally bioavailable inhibitor that selectively targets polo-like kinase 4 (PLK4) with high potency.
DC67425	BMS-986458 Featured	BMS-986458 represents a breakthrough in targeted protein degradation as a first-in-class, orally available PROTAC® molecule that specifically degrades B-cell lymphoma 6 (BCL6).
DC67426	PRT3789 Featured	PRT3789 is a first-in-class proteolysis-targeting chimera (PROTAC) that selectively degrades SMARCA2 (BRM) while exhibiting minimal activity against its closely related paralog SMARCA4 (BRG1).
DC67427	FG-2101 Featured	FG-2101 represents a next-generation antibacterial agent as a potent, orally bioavailable non-hydroxamate inhibitor of LpxC – a key enzyme in Gram-negative bacterial lipopolysaccharide biosynthesis.
DC60819	MSD199 Featured	MSD199 is a potent, and selective Nav1.8 inhibitor with IC50 of 4.7 nM in Qube automated patch-clamp assay, >2000-fold selective over all other Nav isoforms.
DC60820	TAS3351 Featured	TAS3351 is a fourth-generation EGFR-TKI overcoming T790M and C797S-mediated resistance in NSCLC with common mutations. TAS3351 exhibites almost comparable inhibitory potency against cellular phosphorylation of EGFR harboring ex19del or L858R with or without C797S and/or T790M while sparing wild type EGFR activity.
DC60821	Lipid TOT-5 Featured	TOT-5, a tri-oleoyl-Tris ionizable lipid (pKa 6.2), enables splenic B cell-targeted mRNA delivery via 15% DSPC-incorporated LNPs. Its charge-neutral, hydrophobic surface minimizes hepatic ApoE uptake and enhances complement C3 adsorption, facilitating CD21/35-mediated uptake by marginal zone B cells. In vivo, intravenous 15%DSPC-LNPs showed 8-fold higher spleen-to-liver luciferase expression vs 3%DSPC, with anti-CD21/35 blocking 60% B cell uptake. Intramuscular administration induced robust OVA-specific IgG (10^5 titer) and CTL responses (3.5% tetramer+ CD8+ T cells) while reducing hepatotoxicity (ALT/AST levels ≤40 U/L vs SM-102-LNPs' 80-120 U/L). Cryo-ET confirmed stable lamellar structures (80-100 nm, ζ-potential -2 mV). This formulation achieves safe, ligand-free splenic targeting for mRNA vaccines.
DC67428	AMG-193 Featured	AMG 193 represents a novel class of targeted cancer therapeutics as an orally bioavailable, methylthioadenosine (MTA)-dependent PRMT5 inhibitor.
DC67429	(5-METHOXY-3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETIC ACID Featured
DC67430	1H-Benzimidazol-6-amine,2-(4-thiazolyl)- Featured
DC67431	TPBM Featured	TPBM represents a novel class of selective estrogen receptor α (ERα) modulators with a unique mechanism of action.

Products

Customized Consultation X

Your information is safe with us. * Required Fields.